Références:
1. Perk J, De Backer G, Gohlke H et al. for The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal 2012; 33: 1635–1701. doi:10.1093/eurheartj/ehs092.
2. Cox RA, Garcia-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins. In Walker HK, Hall WD, Hurst JW (eds), Clinical Methods: The History, Physical, and Laboratory Monétisation. 3rd edition. Butterworths, Boston, 1990.
3. Iribarren C, Jacobs DR Jr, Slattery ML et al. Epidemiology of low total plasma cholesterol concentration among young adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Prev Med 1997; 26(4): 495-507.
4. Bell KJL, Hayen A, Irwig L et al. When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ 2013; 346: f1895 doi: 10.1136/bmj.f1895.
5. Bérard E, Bongard V, Ruidavets JB et al. Pulse wave velocity, pulse pressure and number of carotid or femoral plaques improve prediction of cardiovascular death in a population at low risk. J Hum Hypertens 2013 Feb 21 (Epub ahead of print]) doi: 10.1038/jhh.2013.8.
6. Pencina MJ. IDI, NRI and different c statistics. HYPERLINK "http://www.lerner.ccf.org/qhs/outcomes/documents/pencina.pdf" http://www.lerner.ccf.org/qhs/outcomes/documents/pencina.pdf
En anglais, consulté en avril 2013.
7. Bongard V, Dallongeville J, Arveiler D et al. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study. Arch Cardiovasc Dis 2013; 106(2): 93-102. doi: 10.1016/j.acvd.2012.11.003.
8. Heber D, Yip I, Ashley JM. Cholesterol-lowering effects of a proprietary Chinese red-yeastrice dietary supplement. Am J Clin Nutr 1999; 69: 231–6.